Literature DB >> 15109617

Urotensin II: the old kid in town.

Döne Onan1, Ross D Hannan, Walter G Thomas.   

Abstract

Urotensin II (U-II) is a vasoactive hormone that acts through a recently described seven transmembrane-spanning G-protein-coupled receptor called GPR14. Although touted as the most potent vasoconstrictor peptide yet identified, the responses elicited by U-II are species-, tissue- and endothelium-dependent. Available data question the contribution of U-II to resting cardiovascular homeostasis in humans; instead they point to a role for this hormone in disease (heart failure and cardiac cell growth, renal function, diabetes, and mitogenesis in vascular and tumour cells). Key features of these diseases are increased expression and activity of U-II receptors. In this review, we focus on recent evidence that supports a role of U-II and its receptor in cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15109617     DOI: 10.1016/j.tem.2004.03.007

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  15 in total

1.  Does cigarette smoking increase plasma urotensin II concentrations?

Authors:  S J Gold; J P Thompson; J P Williams; E E F Helm; J Sadler; W Song; L L Ng; D G Lambert
Journal:  Eur J Clin Pharmacol       Date:  2007-01-25       Impact factor: 2.953

2.  Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.

Authors:  Brian J Holleran; Marie-Eve Beaulieu; Christophe D Proulx; Pierre Lavigne; Emanuel Escher; Richard Leduc
Journal:  Biochem J       Date:  2007-02-15       Impact factor: 3.857

3.  Urantide improves the structure and function of right ventricle as determined by echocardiography in monocrotaline-induced pulmonary hypertension rat model.

Authors:  Yan Wang; Wei Tian; Chunhong Xiu; Ming Yan; Shuya Wang; Yifang Mei
Journal:  Clin Rheumatol       Date:  2018-01-23       Impact factor: 2.980

4.  Urotensin receptors as a new target for CLP induced septic lung injury in mice.

Authors:  Elif Cadirci; Rustem Anil Ugan; Busra Dincer; Betul Gundogdu; Irfan Cinar; Erol Akpinar; Zekai Halici
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-24       Impact factor: 3.000

5.  Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.

Authors:  A M D Watson; M Olukman; C Koulis; Y Tu; D Samijono; D Yuen; C Lee; D J Behm; M E Cooper; K A M Jandeleit-Dahm; A C Calkin; T J Allen
Journal:  Diabetologia       Date:  2013-01-24       Impact factor: 10.122

6.  Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.

Authors:  Patricia N Sidharta; Klaus Rave; Lutz Heinemann; Eleonora Chiossi; Stephan Krähenbühl; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

7.  Form-deprivation myopia in chick induces limited changes in retinal gene expression.

Authors:  Alice M McGlinn; Donald A Baldwin; John W Tobias; Murat T Budak; Tejvir S Khurana; Richard A Stone
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-08       Impact factor: 4.799

8.  Desensitisation of native and recombinant human urotensin-II receptors.

Authors:  Madura S Batuwangala; Girolamo Calo; Remo Guerrini; Leong L Ng; John McDonald; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-13       Impact factor: 3.000

Review 9.  Role of urotensin II and its receptor in health and disease.

Authors:  John McDonald; Madura Batuwangala; David G Lambert
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

10.  Urotensin-II: More Than a Mediator for Kidney.

Authors:  Ayşe Balat; Mithat Büyükçelik
Journal:  Int J Nephrol       Date:  2012-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.